Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

07 April 2021: Articles  Lebanon

Iodine Contrast Complex Rash Responding to Topical Steroids: A Case Report

Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction , Educational Purpose (only if useful for a systematic review or synthesis), Rare coexistence of disease or pathology

Mahmoud El Hussein1ADEF*, Cima Hamieh2ABDEF, Elie Zaghrini1EG

DOI: 10.12659/AJCR.928930

Am J Case Rep 2021; 22:e928930

0 Comments

Abstract

BACKGROUND: Iodine contrast allergy can cause acute and delayed allergic reactions. Just like any other sensitivity reaction, the severity can vary from mild to moderate skin manifestations such as erythematous rash to an even more severe presentation or life-threatening event, such as angioedema and anaphylaxis.

CASE REPORT: This case report discusses a patient who presented to our institution with a diffuse complex rash 2 days after undergoing CT scan imaging with intravenous iodine contrast injection. The rash started by being maculopapular in nature. Later on, the patient developed a purpuric and petechial pattern, and eventually, an acute exanthematous pustulosis rash was noticed. Several attempts to treat the patient with intravenous corticosteroids failed. Three days after admission (5 days after the rash started), topical steroids were used in place of parenteral steroids. The rash showed remarkable improvement in a very short time. The patient was diagnosed with delayed hypersensitivity IV iodine reaction, resistant to parenteral corticosteroids. The workup of such an extensive rash and odd presentation include several laboratory tests and skin testing to be able to rule out more serious differential diagnoses.

CONCLUSIONS: This case is unique as it enables us to show the importance of substituting topical management, more specifically, topical steroids that might even replace parenteral steroids, to our management in order to treat allergic reactions, especially in the presence of a rash.

Keywords: Contrast Media, Exanthema, Steroids, Acute Generalized Exanthematous Pustulosis, Exanthema, Hypersensitivity, Administration, Topical, Anaphylaxis, Iodine

Background

One of the adverse effects of medications is an allergic reaction, which can range from only mild erythema to a life-threatening event. Antibiotics, anti-inflammatories, anesthetics, and anti-epileptics are common triggers for an allergic reaction, not to mention iodine contrast, especially when given through an intravenous (IV) route [1]. Reactions to iodine contrast, also known as radiocontrast-associated hypersensitivity reactions, can range from a benign acute-onset to anaphylaxis. In between these 2 extremes, a delayed onset reaction has been identified, that can start more than 3 hours after exposure, and can be seen after 5 days [1,2]. This allergic reaction presents as skin rash and fever and sometimes presents with end-organ damage [2,3]. However, different types of skin rashes have been reported as a manifestation to IV iodine. Maculopapular erythematous rash, bullae, and blisters, some with xerotic eczema, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis (AGEP), and hypersensitivity vasculitis are all manifestations of iodine-induced skin rashes [3]. Although maculopapular eruptions and erythema, urticaria, and even pustular rashes are commonly seen in an allergic reaction, hypersensitivity vasculitis is a rare finding. Hypersensitivity vasculitis, also referred to as leukocytoclastic vasculitis, is usually seen secondary to an infection, and very rarely is due to a reaction to drugs. The rash evolves 1 week after exposure and is associated with low-grade fever, myalgias, and arthralgias. Also of utmost importance is the possibility of finding multiple rash presentations in the same patient experiencing a delayed sensitivity to IV iodine, such as in this case.

The case we are about to present is interesting not only for its presentation but mainly for its response to an unconventional treatment of listed rashes. Management options range from oral antihistamine to oral and IV steroids. Colchicine and dapsone are also systematically used for hypersensitivity purpuric vasculitis; for resistant rashes on the other hand, the use of immunosuppressant therapy is common [4–6]. Topical management is thought to be reserved for mild cases of urticarial and maculopapular rashes; but this patient, with a complex resistant rash, responded only to topical steroids.

Case Report

A 75-year-old man with multiple comorbidities presented to the Emergency Department with diffuse rash, itching, and facial flushing 48 hours after undergoing abdominal CT scan with iodine IV contrast and 72 hours after the beginning of a diffuse abdominal pain that encouraged his primary care physician (PCP) to order this imaging in the first place. As the pain did not resolve, the patient presented to our care with the previously mentioned symptoms and also with a fever of 38.6°C.

He denied nausea, vomiting, headaches, dyspnea, and wheezes. On physical examination, the patient had mild facial flushing with an extensive maculopapular rash over his trunk, back, neck, buttocks, and lower and upper extremities, involving the palms (Figures 1–3). Upon workup, the patient had an elevated white blood cell count, with no eosinophilia. Elevated CRP was noticed as well as an acute kidney injury (AKI) with hyponatremia. The patient was admitted for further management and was started on IV steroids of 2 mg/kg methylprednisone repeated twice and oral antihistamine and desloratadine 5 mg for 2 days. The patient had received IV iodine contrast on multiple occasions but never experienced a similar reaction.

Review of systems was non-pertinent. His home medications were valproate and topiramate for epilepsy, tamsulosin for prostate hyperplasia, Lisinopril with a hydrochlorothiazide diuretic, and bisoprolol, metformin, and sulfonylurea for diabetes mellitus type II, and esomeprazole for gastritis; none of them is recently added.

After admission, the rash and pruritis did not improve with IV steroids and oral antihistamine, and the lower extremities started developing a non-pitting edema. The patient also developed diffuse arthralgias, with evolution of the rash to petechial and purpuric patterns (Figure 4), and AGEP (Figure 5). A viral serology workup for hepatitis B and C, EBV, CMV, SARS-COV2, and Group A streptococcus antigen and ANA were all negative.

Next, the patient underwent 2 skin-punch biopsies, one from the back and one from the lower extremity; both were consistent with delayed hypersensitivity reaction to iodinated contrast material, with urticarial vasculitis-like patterns. While awaiting the results, the patient was switched from the IV and oral route treatment to topical steroid, clobetasol (propionate) 0.5 mg/g at a dose of 25 mg, which was applied over the whole body on a daily basis. Forty-eight hours later, the patient showed marked improvement and the rash was almost resolved (Figures 6, 7).

The patient was hence diagnosed with delayed hypersensitivity reaction to IV iodine, and treatment was continued for 1 month. Upon follow-up in clinic 1 month after discharge, the patient had resolution of his electrolyte imbalances and AKI, and a complete resolution of his rash.

Discussion

LIMITATIONS: During the management of this case of iodine contrast-induced delayed hypersensitivity reaction, multiple differential diagnoses and underlying etiologies were ruled out. However, the patient did not receive any skin testing, which the literature showed to be helpful in the identification of a T cell-mediated reactions to iodinated contrast. In addition, the fact that the patient had prior exposure to contrast without any documented reaction suggests the importance of skin testing to rule out other causes of this specific allergic reaction [7]. Workup to rule out malignancy should also have been offered to this patient, as the vasculitis he presented with could be a sign of an underlying hematologic or solid malignancy, as it is present in 3.8% of cases [8].

Conclusions

IV iodine contrast may be a cause of a delayed hypersensitivity reactions, causing different kinds of skin rashes. Topical steroids can be an essential part of the treatment regimen, especially if the patient presents with a systemic steroid-resistant rash. The patient in this case most likely had a delayed reaction to iodine contrast, but a definitive diagnosis can only be attained after immunologic and allergen skin testing.

References:

1.. , Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG), 2006 Drug allergies: Overview. [Updated 2020 May 7]. https://www.ncbi.nlm.nih.gov/books/NBK447110/

2.. Macy EM, Current epidemiology and management of radiocontrast-associated acute- and delayed-onset hypersensitivity: A review of the literature: Perm J, 2018; 22; 17-72

3.. Tasker F, Fleming H, McNeill G, Contrast media and cutaneous reactions. Part 2: Delayed hypersensitivity reactions to iodinated contrast media: Clin Exp Dermatol, 2019; 44(8); 844-60

4.. Baigrie D, Bansal P, Goyal A, Leukocytoclastic vasculitis: StatPearls, 2020, Treasure Island (FL), StatPearls Publishing [Updated 2020 Aug 11].

5.. Einhorn J, Levis JT, Dermatologic diagnosis: Leukocytoclastic vasculitis: Perm J, 2015; 19(3); 77-78

6.. Sangolli PM, Lakshmi DV, Vasculitis: A checklist to approach and treatment update for dermatologists: Indian Dermatol Online J, 2019; 10(6); 617-26

7.. Kanny G, Pichler W, Morisset M, T cell-mediated reactions to iodinated contrast media: Evaluation by skin and lymphocyte activation tests: J Allergy Clin Immunol, 2005; 115(1); 179-85

8.. Eastham G, Vleugels RA, Callen J, What are the signs and symptoms of a malignant etiology for leukocytoclastic vasculitis (LCV)?: Medscape, 1999; 42(10); 2204-12

SARS-CoV-2/COVID-19

04 July 2022 : Case report  Italy

Interleukin-6 Is a Promising Marker of COVID-19 in Children: A Case Series of 2 Brothers with Severe COVID-...

Am J Case Rep In Press; DOI: 10.12659/AJCR.934468  

29 June 2022 : Case report  USA

A Clinical Case of COVID-19 Vaccine-Associated Guillain-Barré Syndrome

Am J Case Rep In Press; DOI: 10.12659/AJCR.936896  

16 June 2022 : Case report  Ecuador

Multidrug-Resistant Klebsiella pneumoniae in a Patient with SARS-Cov-2 Pneumonia in an Intensive Care Unit ...

Am J Case Rep In Press; DOI: 10.12659/AJCR.936498  

13 June 2022 : Case report  Japan

Stenotrophomonas maltophilia Infection Associated with COVID-19: A Case Series and Literature Review

Am J Case Rep In Press; DOI: 10.12659/AJCR.936889  

In Press

04 Jul 2022 : Case report  USA

Unusual Case of Mirizzi Syndrome Presenting as Painless Jaundice

Am J Case Rep In Press; DOI: 10.12659/AJCR.936836  

04 Jul 2022 : Case report  Italy

Interleukin-6 Is a Promising Marker of COVID-19 in Children: A Case Series of 2 Brothers with Severe COVID-...

Am J Case Rep In Press; DOI: 10.12659/AJCR.934468  

04 Jul 2022 : Case report  Saudi Arabia

Relapsed Angioimmunoblastic T Cell Lymphoma with Fulminant Leukemic Involvement

Am J Case Rep In Press; DOI: 10.12659/AJCR.936448  

01 Jul 2022 : Case report  Poland

A 75-Year-Old Female Smoker with Advanced Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Per...

Am J Case Rep In Press; DOI: 10.12659/AJCR.936536  

Most Viewed Current Articles

23 Feb 2022 : Case report  USA

Penile Necrosis Associated with Local Intravenous Injection of Cocaine

DOI :10.12659/AJCR.935250

Am J Case Rep 2022; 23:e935250

17 Feb 2022 : Case report  Oman

Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of P...

DOI :10.12659/AJCR.934399

Am J Case Rep 2022; 23:e934399

06 Dec 2021 : Case report  Brazil

Lipedema Can Be Treated Non-Surgically: A Report of 5 Cases

DOI :10.12659/AJCR.934406

Am J Case Rep 2021; 22:e934406

09 Feb 2022 : Case report  Saudi Arabia

Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COV...

DOI :10.12659/AJCR.934744

Am J Case Rep 2022; 23:e934744

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923